One failed trial erased more than a billion dollars from a single biotech’s market value this week. The sector it trades in barely noticed. Both of those facts are true at the same time, and untangling why is more useful than picking a single winner to write about. The Rally’s Math: XBI Up 36% Even…
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Google reCAPTCHA helps protect websites from spam and abuse by verifying user interactions through challenges.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com (opens in a new window)
You can find more information in our Privacy Policy and Privacy Policy.